ClinicalTrials.gg
CompletedNCT04112563COCORICOUpdated Jul 30, 2024

COmparison of White Light and Linked COlor Imaging for Detection of RIght COlon Polyps

An interventional study of exploration in white light (WLI) and Exploration in LCI in Adenoma Colon, Colon Polyp and Colonoscopy, sponsored by Société Française d'Endoscopie Digestive. Completed at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by Société Française d'Endoscopie Digestive · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
686
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Comparison of the number of adenomas missed by the first exploration of the right colon by LCI (linked color imaging) or by white light during a colonoscopy, according to the order of randomization.

Read the detailed description

All patients consecutively admitted for routine colonoscopy will be included in this prospective randomized crossover study. After randomization, a first exploration of the right colon will be performed in linked color imaging (LCI) or white light imaging (WLI) depending of the randomization. Every polyp will be resected as soon it will be detected. After this first examination, colon will be explored a second time with a light system different from the one used for the first exploration. If a polyp will be detected during the second exploration, it will be counted as a polyp missed by the first exploration method.

A- Inclusion criteria:

  1. Patient consecutively admitted to one of the endoscopy units for routine colonoscopy (screening, positive FIT, personal or family history of polyp or cancer, symptoms)
  2. Patient whose age is greater than or equal to 18 years and less than 90 years
  3. Score: ASA 1, ASA 2, ASA 3
  4. No participation in another clinical study
  5. Signed informed consent

Exclusion criteria:

History of recto-colic resection Inadequate preparation (none under Boston score \<2) Patient referred for resection of a polyp in place, known IBD (inflammatory bowel disease) or known polyposis

B- Exclusion criteria:

  1. History of recto-colonic resection
  2. Inadequate preparation (none under Boston score \<2)
  3. Patient referred for resection of a known polyp
  4. Inflammatory Bowel Disease
  5. family polyposis
  6. Score: ASA 4, ASA 5
  7. Pregnant woman
  8. Patient with coagulation abnormalities preventing polyp resection: TP \<50%, Platelets \<50000 / mm3, effective anticoagulation in progress, clopidogrel in progress
  9. Patient unable to personally consent
  10. No signed informed consent

Purposes of the study:

Compare, when exploring the number of adenomas missed by the first exploration of the right colon by LCI or by white light, according to the order of randomization.

Evaluation criteria :

Main criterion:

  • Missed right colon adenomas by first exploration in LCI-WLI and WLI-LCI groups

Secondary criteria

  • Rate of polyps missed by the first exploration
  • Serrated polyp rate missed by the first exploration
  • Advanced adenoma rate missed by the first exploration
  • Comparison of ADR, SPDR, given by the first exploration technique decided by randomization

Number of patients:

The expected rate of "missed adenomas" of the colon is about 20%, based on published data. Considering as relevant an 8% reduction in this rate of "missed adenomas" of the right colon by the LCI, the expected rate for LCI is therefore 12%.

With a risk of the first species of 5% (bilateral test), a power of 80%, 329 patients per group should be included in the study. Taking into account the rate lost to follow-up of 5%, we expect a total of 700 patients.

Duration of the study:

1-2 years

02

Conditions studied

  • Adenoma Colon
  • Colon Polyp
  • Colonoscopy

Browse trials for

03

In context

Colonic Polyps

378 studies on the registry are indexed under Colonic Polyps; 57 are open to participants now.

This study's enrollment of 686 is above the median of 278 across 251 interventional studies indexed under Colonic Polyps.

Browse Colonic Polyps studies →

Lead sponsor

Société Française d'Endoscopie Digestive is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient consecutively admitted for routine colonoscopy

Exclusion criteria

Exclusion Criteria:

  • History of recto-colic resection
  • Inadequate preparation (none under Boston score \<2)
  • Patient referred for resection of a known polyp
  • known Inflammatory Bowel Disease (IBD) or known polyposis
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
686 participants (actual)

Study arms

  • Active comparator
    WLI-LCI group

    a first exploration of the right colon will be done in white light (WLI) then a second exploration will be done in LCI

    Procedure: exploration in white light (WLI) · Procedure: Exploration in LCI

  • Active comparator
    LCI-WLI group

    a first exploration of the right colon will be done in LCI and a second exploration will be done in white light (WLI)

    Procedure: exploration in white light (WLI) · Procedure: Exploration in LCI

Interventions

  • Procedureexploration in white light (WLI)

    Exploration of the right colon done in white light (WLI)

  • ProcedureExploration in LCI

    Exploration of the right colon in linked color imaging (LCI)

06

What researchers measure

Primary outcomes

  1. the number of missed adenomas during the first exploration of the right colon

    Number of polyps diagnosed on the second exploration and not removed (because not diagnosed) during the first exploration

    Time frame: 1 day

Secondary outcomes

  1. The factors influencing these missed polyp rates

    Time of exploration (in seconds)

    Time frame: 1 day

  2. The factors influencing these missed polyp rates

    Boston scale (0 to 9)

    Time frame: 1 day

  3. The characteristics of the missed polyps

    Size in millimeters

    Time frame: 1 day

  4. The characteristics of the missed polyps

    type : Adenoma polyp / Advanced neoplasia polyp / Serrated polyp / Hyperplastic polyp

    Time frame: 1 day

  5. Adenoma Detection Rate (ADR)

    given by the first exploration technique decided by randomization: percentage of colonoscopy with one or more adenoma of the right colon

    Time frame: 1 day

  6. Advanced Neoplasia Detection Rate (ANDR)

    given by the first exploration technique decided by randomization: percentage of colonoscopy with one or more advanced neoplasia of the right colon

    Time frame: 1 day

  7. Serrated Polyp Detection Rate (SPDR)

    given by the first exploration technique decided by randomization: percentage of colonoscopy with one or more serrated polyp of the right colon

    Time frame: 1 day

07

Study locations

1 site
  • Clinique Paris-Bercy
    Charenton-le-Pont, 94220, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Dec 2022, 35 months.

Of 133 non-industry interventional studies with no phase under Colonic Polyps, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's 35 months is above that.

Counting every sponsor, half of 150 studies reached it within 17 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2019
First posted
Oct 2, 2019
StartActual
Jan 1, 2020
Primary completionActual
Dec 22, 2022
CompletionActual
Dec 29, 2022
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04112563
Lead sponsor
Société Française d'Endoscopie Digestive
Responsible party
KARSENTI (Principal investigator, Société Française d'Endoscopie Digestive) — Principal investigator
First posted
Oct 2, 2019
Start date
Jan 1, 2020
Primary completion
Dec 22, 2022
Completion
Dec 29, 2022
Last update
Jul 30, 2024

Study contacts

David KARSENTI, MD
principal investigator · Société Française d'Endoscopie Digestive

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion